Citigroup downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a buy rating to a neutral rating in a report released on Thursday morning, The Fly reports. The brokerage currently has $19.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a buy rating to a hold rating and set a $15.00 target price for the company. in a research note on Saturday, October 5th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, October 2nd. Stifel Nicolaus restated a hold rating and issued a $17.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, October 16th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. Vanda Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $26.71.
NASDAQ:VNDA traded up $0.21 during trading hours on Thursday, hitting $14.74. The company’s stock had a trading volume of 787,900 shares, compared to its average volume of 762,937. Vanda Pharmaceuticals has a 52-week low of $11.83 and a 52-week high of $33.44. The stock has a market capitalization of $719.20 million, a P/E ratio of 30.71 and a beta of 0.29. The stock has a fifty day moving average of $13.51 and a 200-day moving average of $14.36.
In related news, SVP Timothy Williams sold 2,575 shares of Vanda Pharmaceuticals stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total transaction of $37,826.75. Following the transaction, the senior vice president now owns 57,425 shares in the company, valued at approximately $843,573.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard W. Dugan sold 15,000 shares of Vanda Pharmaceuticals stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.85, for a total transaction of $222,750.00. Following the transaction, the director now owns 50,770 shares in the company, valued at approximately $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the stock. North Star Investment Management Corp. acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter valued at $66,000. Meeder Asset Management Inc. lifted its holdings in Vanda Pharmaceuticals by 1,638.3% in the 3rd quarter. Meeder Asset Management Inc. now owns 5,215 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 4,915 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Vanda Pharmaceuticals in the 2nd quarter worth $138,000. Clarus Wealth Advisors acquired a new position in Vanda Pharmaceuticals in the 3rd quarter worth $133,000. Finally, Zebra Capital Management LLC acquired a new position in Vanda Pharmaceuticals in the 2nd quarter worth $170,000.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.